Diamedica Therapeutics Inc Stock Price, News & Analysis

DiaMedica Therapeutics (NASDAQ: DMAC) announced a poster presentation at the 11th European Stroke Organisation Conference (ESOC 2025) in Helsinki, Finland from May 21-23, 2025. The poster (P-704) will present safety and clinical outcomes data from the ReMEDy2 study, a pivotal phase 2/3 trial of DM199 (rinvecalinase alfa) in acute ischemic stroke patients.

Dr. John J. Volpi, a ReMEDy2 trial Scientific Advisory Board Member, will be available on May 22, 2025, to answer questions about the poster titled "Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only." The company will also exhibit at booth D4.1.

DiaMedica Therapeutics (NASDAQ: DMAC) reported Q1 2025 financial results and provided business updates. The company is advancing two key clinical programs: DM199 for preeclampsia and acute ischemic stroke. Topline results from Phase 2 Part 1A preeclampsia trial are expected between late June and early July 2025, with Phase 2 Part 1B set to begin in Q3 2025. The Phase 2/3 ReMEDy2 trial for acute ischemic stroke is progressing as planned, with interim analysis of first 200 patients expected in H1 2026. Financially, DMAC reported cash position of $37.3 million as of March 31, 2025, providing runway into Q3 2026. Q1 2025 saw increased R&D expenses of $5.7M (vs $3.7M in Q1 2024) and net loss of $7.7M ($0.18/share) compared to $5.2M ($0.14/share) in Q1 2024.

DiaMedica Therapeutics (NASDAQ: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in three major investor conferences in May 2025. The company will attend the RBC Capital Markets Global Healthcare Conference (May 20-21) and the H.C. Wainwright BioConnect Conference (May 20) in New York City, where management will conduct a fireside chat at 3:30 PM ET. Additionally, DiaMedica will participate in the Craig-Hallum Institutional Investor Conference in Minneapolis on May 28.

DiaMedica's primary focus is developing novel treatments for severe ischemic diseases, with their lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein, targeting conditions such as preeclampsia and acute ischemic stroke.

DiaMedica Therapeutics (NASDAQ: DMAC) has announced it will release its first quarter 2025 financial results after market close on Tuesday, May 13th, followed by a conference call on Wednesday, May 14th at 7:00 AM CT. The company, which focuses on developing treatments for preeclampsia and acute ischemic stroke, will provide a business update during the call.

The conference call will be accessible via webcast at https://app.webinar.net/24NpV0mjklG or by dialing (800) 836-8184 with Conference ID 93262. DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant form of the KLK1 protein, which has established therapeutic applications in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.

DiaMedica Therapeutics (DMAC) reported its full year 2024 financial results and provided key business updates. The company is advancing two main clinical programs: a Phase 2/3 trial for acute ischemic stroke (ReMEDy2) and a Phase 2 trial for preeclampsia.

Key financial highlights include:

• Cash position of $44.1 million as of December 31, 2024
• Net loss of $24.4 million ($0.60 per share)
• R&D expenses increased to $19.1 million
• G&A expenses decreased to $7.6 million

The company expects preliminary topline safety and efficacy data from Part 1A of the preeclampsia study in Q2 2025. The ReMEDy2 trial has reached 30 activated hospital sites, with interim analysis expected in H1 2026. Cash runway extends into Q3 2026.

DiaMedica Therapeutics (Nasdaq: DMAC) announced it will release its full-year 2024 financial results after market close on March 17th, 2025, followed by a conference call on March 18th at 7:00 AM Central Time. The company will provide a business update during the call.

DiaMedica is a clinical-stage biopharmaceutical company developing treatments for severe ischemic diseases. Their lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, targeting acute ischemic stroke and preeclampsia. The protein has established therapeutic applications in Asia for treating various vascular diseases.

DiaMedica Therapeutics (Nasdaq: DMAC) has appointed Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. O'Connor brings significant biopharmaceutical industry experience, most notably as CEO of Ambrx Biopharma, where he led the company from a $40 million valuation to a $2 billion acquisition by Johnson & Johnson in just 14 months.

DiaMedica is developing treatments for acute ischemic stroke (AIS) and preeclampsia (PE). AIS accounts for 87% of all strokes and is the leading cause of combined mortality and morbidity worldwide. PE affects 50,000 severe cases annually in the United States. O'Connor's expertise spans capital markets, licensing, business development, corporate strategy, clinical development, and regulatory compliance.

O'Connor is a former U.S. Marines Captain, holds a BA from Boston University and a JD from Penn State Dickinson Law, and has served on multiple public company boards and as Vice Chairman of BioNJ.

DiaMedica Therapeutics (Nasdaq: DMAC) announced a peer-reviewed publication in the journal Stroke detailing DM199's mechanism of action for treating acute ischemic stroke (AIS). The article, scheduled for print in February 2025, explains how DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, works as a bradykinin-producing enzyme to enhance collateral circulation and stimulate angiogenesis.

The research shows that in acute stroke animal studies, bradykinin B2 receptor expression increased 36-fold on brain endothelial cells in ischemic regions. DM199 generates bradykinin that induces local vasodilation and improves brain perfusion through three synergistic signaling pathways. The treatment's preferential effect on ischemic tissue helps avoid systemic adverse effects like hypotension when properly dosed.

The prior Phase 2 ReMEDy1 trial showed favorable clinical outcomes in AIS patients ineligible for mechanical thrombectomy. The mechanism is currently being studied in the ongoing Phase 2/3 ReMEDy2 Trial.

DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025, at 11:20am Eastern Time.

The company specializes in developing novel treatments for severe ischemic diseases, with their lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein. This therapeutic approach has established presence in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.

Investors interested in meeting with DiaMedica's management during the conference can arrange meetings through their Oppenheimer representative.